Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for type 2 diabetes, have recently emerged as promising candidates for addiction treatment (Klausen et al., 2022). Here, GLP1R is linked to type 2 diabetes mellitus.